Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12768228 | 0.89 | — | — | |
| SCHEMBL13488803 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL12697568 | 0.79 | ALDH1A1 (0.38) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL2495634 | 0.74 | SLC5A2 (0.42) | ALDH1A1LMNA | |
| SCHEMBL12697555 | 0.70 | ABL1 (0.44) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL7639592 | 0.68 | ALB (0.44) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL20750696 | 0.68 | ALB (0.44) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL13065052 | 0.64 | BLM (0.48) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL5638638 | 0.63 | LMNA (0.42) | ALDH1A1LMNAALBMAPK1ABL1 | |
| SCHEMBL30310987 | 0.63 | TK1 (0.57) | ALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275538-B1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | TAGCYX BIOTECHNOLOGIES (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-8426569-B2 | DNA capable of being amplified by PCR with high selectivity and high efficiency | RIKEN (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8426569-B2 | DNA capable of being amplified by PCR with high selectivity and high efficiency | RIKEN (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8426569-B2 | DNA capable of being amplified by PCR with high selectivity and high efficiency | RIKEN (JP) | 2013-04-23 | — | — | US | disclosed |
| EP-1970445-B1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | RIKEN (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20110053782-A1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | RIKEN (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053782-A1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | RIKEN (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053782-A1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | RIKEN (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2275538-A1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | Riken (JP) | 2011-01-19 | — | — | EP | disclosed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053782-A1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | POLRMT, POLN, POLL | ALDH1A1 2881/4885LMNA 1568/4885ALB 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.